```html

Jerusalem Mycetoma – Comprehensive Medical Guide

Overview

Jerusalem mycetoma (also called Mycetoma pedis or Eumycetoma of the foot) is a chronic, progressive subcutaneous infection that most often involves the foot but can affect any part of the lower extremity. The disease is caused by a fungal species of the genus Madurella, primarily Madurella mycetomatis, which was historically first described in patients from the Jerusalem region, hence the eponym.

It belongs to the broader group of **mycetomas**, which are classified as either:

• Eumycetoma – caused by true fungi (the type seen in Jerusalem mycetoma).
• Actinomycetoma – caused by filamentous bacteria.

While mycetoma is a global disease, the highest burden is reported in tropical and subtropical zones, especially Africa, India, and the Middle East. Estimates from the World Health Organization (WHO) suggest there are **~1.5 million active cases worldwide**, with **≈0.5–1%** of those occurring in the Levant region, including Israel and the Palestinian territories. The condition most commonly affects **young adult males (15‑40 years)** who work outdoors barefoot or with inadequate foot protection.

Symptoms

The presentation is usually insidious, developing over months to years. Common signs and symptoms include:

Early (Inflammatory) Phase

• Painful swelling of the affected area, often after a minor puncture wound.
• Redness (erythema) and warmth over the lesion.
• Fever or low‑grade chills may occur but are not universal.

Chronic (Granulomatous) Phase

• Firm subcutaneous nodules that coalesce into a larger mass.
• Multiple sinuses (draining tracts) that open to the skin surface.
• Discharge of granules (“grains”) – tiny black, white, or yellowish particles that are the fungal colonies.
• Progressive deformity of the foot or hand, leading to difficulty walking or using the limb.
• Secondary bacterial infection – increased pain, pus, foul odor.

Late Complications

• Joint involvement (arthritis) due to spread into adjacent joints.
• Bone destruction (osteomyelitis) visible on X‑ray.
• Amputation in severe, untreated cases.

Causes and Risk Factors

Jerusalem mycetoma is an environmental disease. The fungus lives in soil and decaying plant material. Infection occurs when the organism is introduced into the subcutaneous tissue, usually after a puncture wound.

Primary Causes

• Traumatic inoculation (thorn, nail, animal bite, contaminated needle).
• Walking barefoot or wearing open sandals in endemic areas.
• Occupational exposure – agriculture, herding, construction.

Risk Factors

• Geographic location: Native or long‑term residence in endemic regions (e.g., Israel, Jordan, Sudan, India).
• Age & gender: Males 15‑40 y, because of occupational exposure.
• Socio‑economic status: Limited access to protective footwear and health care.
• Immunosuppression: HIV, diabetes, chronic steroid use may accelerate spread, though most cases occur in immunocompetent individuals.
• Previous skin trauma in the same area.

Diagnosis

Because early lesions mimic bacterial abscesses or other skin conditions, a high index of suspicion is essential, especially in endemic areas.

Clinical Evaluation

• Detailed history of exposure and wound.
• Physical exam documenting swelling, sinuses, and grain discharge.

Laboratory & Imaging Studies

1. Grain examination – direct microscopy of discharged grains using KOH or Calcofluor white; fungal hyphae appear as thin, septate filaments.
2. Culture – grains are placed on Sabouraud dextrose agar; M. mycetomatis grows slowly (2‑4 weeks) forming dark colonies.
3. Histopathology – biopsy of the lesion shows granulomatous inflammation with fungal grains surrounded by Splendore‑Hoeppli material.
4. Imaging:
   • Ultrasound – shows hypoechoic masses with internal echoes (“dot‑in‑circle” sign).
   • X‑ray – detects bone involvement; late disease shows osteolysis.
   • MRI – best for delineating soft‑tissue spread and planning surgery.
5. Serology – not routinely used; PCR‑based assays are emerging but not widely available.

Diagnostic Criteria (WHO 2022)

A diagnosis is confirmed when any two of the following are present:

• Characteristic clinical triad (mass, sinuses, grains).
• Positive direct microscopy or culture for a eumycetoma fungus.
• Imaging consistent with mycetoma (e.g., “dot‑in‑circle” sign on MRI).

Treatment Options

Management requires a combination of prolonged antifungal therapy and, in many cases, surgical intervention.

Medical Therapy

Drug	Typical Dose	Duration	Notes
Itraconazole	400 mg daily (divided BID)	12‑24 months (until clinical cure + 6 months of negative cultures)	Best‑studied; monitor liver function every 2‑4 weeks.
Posaconazole (delayed‑release)	300 mg daily after loading 400 mg BID × 2 days	12‑18 months	Effective for itraconazole‑resistant isolates; expensive.
Voriconazole	200 mg BID	6‑12 months (selected cases)	Useful when drug‑susceptibility testing shows low MIC; monitor visual side‑effects.

Therapeutic drug monitoring (TDM) is recommended for itraconazole and voriconazole to ensure adequate serum levels.

Surgical Management

• Wide local excision – removal of the mass with a margin of healthy tissue; often combined with skin grafting.
• Debulking – reduces fungal load before prolonged antifungal therapy.
• Amputation – reserved for end‑stage disease with irreversible bone destruction, severe pain, or life‑threatening infection.

Current guidelines advise that surgery should be performed **after at least 4–6 months of antifungal therapy** to reduce recurrence.

Adjunctive Measures

• Wound care – regular dressing changes, keeping sinuses clean.
• Physical therapy – maintains range of motion and prevents contractures.
• Management of secondary bacterial infection with appropriate antibiotics.

Living with Jerusalem Mycetoma

Long‑term management focuses on adherence to medication, monitoring for side effects, and maintaining functional ability.

Practical Tips

1. Medication adherence: Use a weekly pill organizer; set alarms; keep a medication diary.
2. Follow‑up appointments: See your infectious‑disease specialist every 2–3 months for labs and clinical assessment.
3. Skin hygiene: Clean sinuses daily with saline; avoid harsh antiseptics that can irritate tissue.
4. Foot protection: Wear sturdy, closed‑toe shoes; change socks daily.
5. Nutrition: Adequate protein and vitamin D support wound healing.
6. Psychosocial support: Join patient support groups; consider counseling if chronic pain or body image concerns arise.

Monitoring

• Blood tests every 1–2 months (CBC, LFTs, renal function).
• Imaging (ultrasound or MRI) every 6 months to track disease regression.
• Annual ophthalmologic exam if on voriconazole.

Prevention

Because Jerusalem mycetoma is acquired from the environment, primary prevention revolves around reducing skin trauma and exposure.

• Wear protective footwear (closed, leather or thick rubber shoes) when walking in fields, farms, or construction sites.
• Maintain good foot hygiene – wash feet daily, keep nails trimmed.
• Prompt wound care – clean any puncture wound immediately with soap and clean water; apply an antiseptic and cover.
• Public health education – community programs in endemic regions that distribute shoes and teach early‑recognition signs.
• Environmental control – discourage grazing of livestock in densely populated residential zones to limit spore dispersion.

Complications

If left untreated or inadequately treated, Jerusalem mycetoma can lead to serious morbidity:

• Chronic pain and disability – limiting ambulation, work capacity, and quality of life.
• Secondary bacterial infection – cellulitis, sepsis.
• Osteomyelitis – bone loss requiring extensive surgical reconstruction.
• Functional deformity – clawing of toes, altered gait.
• Amputation – up to 30% of severe cases in regions without early treatment (WHO, 2022).
• Psychological impact – depression, anxiety, social stigma.

When to Seek Emergency Care

---

References (selected):

• Mayo Clinic. “Mycetoma – Overview.” 2023.
• World Health Organization. “Mycetoma – A Neglected Tropical Disease.” Technical Report, 2022.
• Cleveland Clinic. “Eumycetoma (Fungal Mycetoma).” 2024.
• Harrington, S. et al. “Current Antifungal Strategies for Eumycetoma.” Clinical Infectious Diseases, 2021; 73(8): 1465‑1472.
• Al‑Saadi, R. & Hafez, A. “Epidemiology of Mycetoma in the Middle East.” Journal of Tropical Medicine, 2022; 27: 112‑119.

```